Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.

Saved in:
Bibliographic Details
Title: Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.
Authors: Patel SP; UC San Diego Health Moores Cancer Center, La Jolla, California, USA spatel@ucsd.edu., Fisher J; University of Washington, Seattle, Washington, USA., Chae YK; Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Soto LS; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kasi A; KUMC, Kansas City, Kansas, USA., Konda B; Internal Medicine, Division Of Medical Oncology, The Ohio State University, Columbus, Ohio, USA., Walshauser M; Cancer Care Center of O'Fallon, O'Fallon, Illinois, USA., Parra E; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang J; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Hosuton, Texas, USA., Duault C; Institute for Immunity, Transplantation, Infections, Stanford University School of Medicine, Stanford, California, USA., Gonzalez-Kozlova E; Precision Immunology Institute and Tisch Cancer Institute, Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Manyam G; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chen H; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Duose DY; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Laberiano Fernandez C; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Luthra R; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Al-Atrash G; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Maecker HT; Stanford University School of Medicine, Stanford, California, USA., Wistuba II; University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gnjatic S; Medicine - Hem/Onc, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Lee JJ; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Hosuton, Texas, USA., Zhang J; Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, UK., Magner CM; SWOG, San Antonio, Texas, USA., Chen HX; CTEP, National Cancer Institute, Bethesda, Maryland, USA., Sharon E; National Cancer Institute, Bethesda, Maryland, USA., Othus M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Ryan CW; OHSU, Portland, Oregon, USA., Blanke C; OHSU, Portland, Oregon, USA., Haymaker CL; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kurzrock R; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Jun 30; Vol. 13 (6). Date of Electronic Publication: 2025 Jun 30.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-011760